The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://keithglbt098347.bloggazza.com/37599539/retatrutide-vs-tirzepatide-a-comparative-analysis